Originally posted here: Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
Originally posted here: Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
Read the original: Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
Read the rest here: Vincera Pharma Announces Completion of Business Combination and Listing on Nasdaq
Continued here:Tauriga Sciences Inc. to Expand its Existing Product Line of CBD Infused Bath Bombs, Branded Under the Tauri-Gum Name
View post: Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
Read the rest here: Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in...
Read more here: UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering
View original post here: Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
The rest is here: Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
Read more from the original source: Acasti Pharma Unaware of Any Material Change
Recent Comments